



cytoactiv[®] HPV-L1 risk profile

for HPV high risk/p16 positivity



Shown are the cytoactiv[®] risk profiles for CIN2+/CIN3+ and HPV high risk or p16+ ASC-US resp. LSIL/HSIL.



① If there is a L1 positive ASC-US, the risk for CIN2+ is 8.3% (transient HPV infection).
If there is a L1 negative ASC-US, the risk for CIN2+ is 55% (precancer).

② If there is a L1 positive LSIL, the risk for CIN3+ is 7.7% resp. 29.7% in a L1 positive HSIL.
If there is a L1 negative LSIL, the risk for CIN3+ is 82.5% resp. 95.8% in a L1 negative HSIL.

H. Griesser et al. 2009, HPV vaccine protein L1 predicts disease outcome of high-risk HPV+ early dysplastic lesions. Am J Clin Pathol
G. Mehlhorn et al. 2013, HPV L1 detection discriminates cervical precancer from transient HPV infection: a prospective international multicenter study. Nature-Modern Pathology, 26
E. Y. Ki et al. 2019, Utility of human papillomavirus L1 capsid protein and HPV test as prognostic markers for cervical intraepithelial neoplasia 2+ in women with persistent ASCUS /LSIL cervical cytology, Int J Med Sci Vol. 16
S.J. Lee et al. 2014, Clinicopathological Implications of Human Papilloma Virus (HPV) L1 Capsid Protein Immunoreactivity in HPV16 – Positive Cervical Cytology. Int J of Med Sciences, 11(1)
Y.S. Choi et al. 2010, Human Papillomavirus L1 Capsid Protein and Human Papillomavirus Type 16 as Prognostic Markers in Cervical Intraepithelial Neoplasia 1, Int J of Gynecol Cancer